Table 2.
Anti-spliced hPPI proliferative responses in T1D HLA-DQ8 patients.
| T1D patients restricted to HLA-DQ8 | |||||||
|---|---|---|---|---|---|---|---|
| Peptide | Responses (proliferation index) | Frequencies of recognition (mean ± 3SD) | |||||
| Recent-onset T1D patients (n = 11) | Controls (n = 12) | p-value | T1D patients (n = 11) | Controls (n = 12) | p-value | ||
| sp-hPPI55-74 | 1.92 (1–3.48) | 0.95 (0.65–1.49) | ≤0.0001 | 7/11 | 1/12 | ≤0.009 | |
| sp-hPPI52-74 | 1.35 (0.77–2.86) | 0.82 (0.51–1.32) | ≤0.002 | 8/11 | 1/12 | ≤0.003 | |
| sp-hPPI51-77 | 0.82 (0.2–1.6) | 0.61 (0.33–1.01) | 2/11 | 0/12 | |||
| T1D patients restricted to HLA-DQ2/DQ8 | |||||||
| Peptide | Responses (proliferation index) | Frequencies of recognition (mean ± 3SD) | |||||
| Recent-onset T1D patients (n = 19) | Controls (n = 12) | p-value | T1D patients (n = 19) | Controls (n = 12) | p-value | ||
| sp-hPPI55-74 | 1.58 (0.6–4.64) | 0.82 (0.51–1.32) | ≤0.008 | 11/19 | 1/12 | ≤0.02 | |
| sp-hPPI52-74 | 1.44 (0.4–4.03) | 0.82 (0.51–1.32) | ≤0.03 | 10/19 | 1/12 | ≤0.02 | |
| sp-hPPI51-77 | 1.08 (0.12–3.21) | 0.61 (0.33–1.01) | 6/19 | 0/12 | |||